Sleep-wake and circadian behavior in brain-specific sirtuin 1 knockout mice and effects of nicotinamide mononucleotide supplementation.

Sakai N, Yoshimoto R, Yamaguchi D, Nishino S

Scientific reports23 Jun 2026

PMID42337335PMCIDPMC13578272DOI10.1038/s41598-026-57888-2PepBankPUB-42337335

Summary

Sirtuin 1 (SIRT1) is implicated in sleep regulation, but there have been a limited number of sleep studies related to SIRT1. We aim to determine the impacts of the brain-specific loss of SIRT1 on sleep and circadian rhythm. We first characterized circadian periods and sleep phenotypes in baseline and recovery sleep in brain-specific Sirt1 knockout (BKO) and littermate wild-type (WT) mice. We found that there were no differences in sleep architecture, amount of each vigilance state, and sleep homeostasis between genotypes, suggesting that brain SIRT1 functionally plays minor roles in sleep-wake regulation. However, in accordance with prior work, loss of Sirt1 caused decreased delta power during non-REM sleep. In addition, there was no difference in intrinsic circadian periods between genotypes. We also provide the first preclinical evidence of whether nicotinamide mononucleotide (NMN) treatment directly improves sleep by administering it acutely (intraperitoneally for 10 days) and chronically (orally for 2 months). However, neither acute nor chronic treatment changed sleep duration and quality compared to the control session in middle-aged WT and BKO mice. Considering our findings and previous studies, the clinically reported improvement in muscle function and energy metabolism may indirectly contribute to the potential benefits of NMN on sleep quality and fatigue in the elderly.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In middle-aged WT and BKO mice, acute NMN did not change sleep duration versus the control session.
In plain wordsIn mice, acute NMN did not change sleep duration compared with the control session.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSleep duration after acute treatment
Study
mousen: not reported in source
Middle-aged WT and brain-specific Sirt1 knockout mice
Comparator
Control session
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · intraperitoneal · 10 daysAs given in this study (mouse).
Source sentences
Summary
However, neither acute nor chronic treatment changed sleep duration and quality compared to the control session in middle-aged WT and BKO mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We also provide the first preclinical evidence of whether nicotinamide mononucleotide (NMN) treatment directly improves sleep by administering it acutely (intraperitoneally for 10 days) and chronically (orally for 2 months).
Show in the study text Report a problemFND-4233733501
02AnimalAnimal study (in vivo)Efficacy outcome
In middle-aged WT and BKO mice, acute NMN did not change sleep quality versus the control session.
In plain wordsIn mice, acute NMN did not change sleep quality compared with the control session.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSleep quality after acute treatment
Study
mousen: not reported in source
Middle-aged WT and brain-specific Sirt1 knockout mice
Comparator
Control session
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · intraperitoneal · 10 daysAs given in this study (mouse).
Source sentences
Summary
However, neither acute nor chronic treatment changed sleep duration and quality compared to the control session in middle-aged WT and BKO mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We also provide the first preclinical evidence of whether nicotinamide mononucleotide (NMN) treatment directly improves sleep by administering it acutely (intraperitoneally for 10 days) and chronically (orally for 2 months).
Show in the study text Report a problemFND-4233733502
03AnimalAnimal study (in vivo)Efficacy outcome
In middle-aged WT and BKO mice, chronic NMN did not change sleep duration versus the control session.
In plain wordsIn mice, chronic NMN did not change sleep duration compared with the control session.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSleep duration after chronic treatment
Study
mousen: not reported in source
Middle-aged WT and brain-specific Sirt1 knockout mice
Comparator
Control session
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · oral · 2 monthsAs given in this study (mouse).
Source sentences
Summary
However, neither acute nor chronic treatment changed sleep duration and quality compared to the control session in middle-aged WT and BKO mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We also provide the first preclinical evidence of whether nicotinamide mononucleotide (NMN) treatment directly improves sleep by administering it acutely (intraperitoneally for 10 days) and chronically (orally for 2 months).
Show in the study text Report a problemFND-4233733503
04AnimalAnimal study (in vivo)Efficacy outcome
In middle-aged WT and BKO mice, chronic NMN did not change sleep quality versus the control session.
In plain wordsIn mice, chronic NMN did not change sleep quality compared with the control session.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
No significant changeSleep quality after chronic treatment
Study
mousen: not reported in source
Middle-aged WT and brain-specific Sirt1 knockout mice
Comparator
Control session
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · oral · 2 monthsAs given in this study (mouse).
Source sentences
Summary
However, neither acute nor chronic treatment changed sleep duration and quality compared to the control session in middle-aged WT and BKO mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We also provide the first preclinical evidence of whether nicotinamide mononucleotide (NMN) treatment directly improves sleep by administering it acutely (intraperitoneally for 10 days) and chronically (orally for 2 months).
Show in the study text Report a problemFND-4233733504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.